NCT01439893终止3 期
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Zensun Sci. & Tech. Co., Ltd.4 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 4
- 主要终点
- Left Ventricular Ejection Fraction
研究概览
简要总结
This is a multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on cardiac remodeling, as well as safety in patients with chronic heart failure.
详细描述
RhNRG-1(recombinant human neuregulin-1)directly works on the cardiomyocytes and restored the normal structure and function of it.Both the preclinical trial and phase II clinical trail have confirmed that rhNRG-1 effectively improved the heart function, and is tolerated in the effective dosage groups. The aim of this phase III trial is to further confirm in large population that rhRNG-1 administration can effectively improve the cardiac remodeling and is tolerated in patients with chronic heart failure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 75, both sex.
- •Left ventricular ejection fraction (LVEF)≤40% (ECHO).
- •NYNA functional class II~III.
- •Definitely diagnosed with chronic systolic heart failure (including medical records, symptoms and physical signs)and clinical symptom is steadily in the latest 1 month.
- •Receiving standard basic treatment of heart failure, has reached the objective dosage or the highest tolerated dosage for at least 1 month, or the dosage has not been changed for at least 1 month.
- •Capable of signing the informed consent form.
排除标准
- •Patients with atrial fibrillation.
- •Patients with a pacemaker.
- •Patient with a metallic implant.
- •Patient with Claustrophobia.
- •Patients with acute myocardial infarction, Hypertrophic cardiomyopathy, constrictive pericarditis, significant valvular pathological change or congenital heart diseases, severe pulmonary artery hypertension.
- •Ischemic heart failure without recanalization or with recanalization in recent six months.
- •Cardiac surgery or cerebrovascular accident within recent six months.
- •Preparing for heart transplantation or has received CRT treatment.
- •Serious hepatic or renal dysfunction caused by organic pathological changes (Cr>2.0mg/dl, AST or ALT 5 times above the normal upper limit).
- •Patients need mechanical ventilation.
- •Systolic blood pressure <90mmHg or >160mmHg.
- •Patients with acute hemodynamic disorder or decompensation in the last 1 month.
- •Serious ventricular arrhythmia (multi-morphological premature ventricular contraction, frequent paroxysmal ventricular tachycardia).
- •Serum potassium <3.2 mmol/L or >5.5 mmol/L.
- •Pregnant or plan to pregnant.
- •Unmarried or married but not procreated women at child-bearing age.
- •Subject with a life expectancy less than 6 months as assessed by the investigator.
- •Patients who participated in any clinical trial in the recent three months.
- •History of any malignancy or suffering from cancer,or biopsy proven pre-malignant condition (eg DICS or cervical atypia).
- •Evidence (physical examination,CXR,ECHO or other tests) shows some active malignancy or adenoidal hypertrophy or neoplasm has effect on heart function or endocrine system, eg pheochromocytoma or hyperthyroidism.
- •Judging by the investigator, the patients could not complete the study or adhere to the study requirements (due to the management reasons or others).
研究组 & 干预措施
rhNRG-1
Active Comparator
Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
干预措施: rhNRG-1 (Drug)
Placebo
Placebo Comparator
Excipient placebo in addition to basic therapy of chronic heart failure
干预措施: Placebo (Drug)
结局指标
主要结局
Left Ventricular Ejection Fraction
时间窗: 30 days
次要结局
- Left Ventricular Ejection Fraction(90 days)
- N-terminal pro-BNP(30 days and 90 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)Atopic DermatitisNCT03269773Kang Stem Biotech Co., Ltd.197
已完成
3 期
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 WeeksNon-erosive Reflux DiseaseNCT03591653Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.291
已完成
3 期
A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisNCT05975268Shanghai Junshi Bioscience Co., Ltd.747
尚未招募
3 期
Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride MonotherapyType 2 Diabetes MellitusNCT05326490PegBio Co., Ltd.546
招募中
3 期
Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19COVID-19NCT05908071Shenzhen Kexing Pharmaceutical Co., Ltd.1,200